PMID- 36736060
OWN - NLM
STAT- MEDLINE
DCOM- 20230516
LR  - 20230517
IS  - 2468-2942 (Electronic)
IS  - 2468-2942 (Linking)
VI  - 35
DP  - 2023
TI  - Real-world comparison of survival outcomes with cisplatin versus carboplatin in 
      patients with limited-stage small-cell lung cancer.
PG  - 100686
LID - S2468-2942(23)00007-2 [pii]
LID - 10.1016/j.ctarc.2023.100686 [doi]
AB  - INTRODUCTION: Limited-stage small-cell lung cancer (LS-SCLC) is potentially 
      curable with concurrent chemoradiation (CRT). Cisplatin is the preferred platinum 
      for the chemotherapy backbone in national guidelines. Unfortunately, many LS-SCLC 
      patients are elderly, with comorbidities and poor performance status (PS), which 
      preclude the use of cisplatin. Carboplatin may be a suitable alternative. This 
      analysis evaluates the overall survival (OS) and time to next treatment (TTNT) in 
      LS-SCLC patients receiving concurrent CRT by platinum use. MATERIALS AND METHODS: 
      The study included LS-SCLC patients in the Flatiron Health nationwide 
      de-identified electronic health record-derived database who received CRT in 
      2013-2019 with follow-up through May 2020. TTNT and OS were compared using both 
      unadjusted and inverse propensity-weighted Cox proportional hazards models. 
      RESULTS: This study included patients treated with carboplatin (n = 600) or 
      cisplatin (n = 572) in combination with etoposide and radiation. Cisplatin 
      patients were younger, had a shorter time from diagnosis to radiation, and had 
      less kidney disease. In an unadjusted analysis, median overall survival (mOS) was 
      greater in the cisplatin group than the carboplatin group with mOS of 22.3 months 
      vs. 19.2 months and Hazard Ratio (HR) of 0.83 (p = 0.01). In the inverse 
      propensity-weighted analysis, this difference was no longer significant (HR 0.93, 
      p = 0.37). No differences were seen in TTNT. CONCLUSION: When balancing on key 
      clinical factors, we observed no statistical difference in OS or TTNT by platinum 
      choice in real-world LS-SCLC patients treated with CRT.  Although observational, 
      the results from this large data set are consistent with the hypothesis that 
      either cisplatin or carboplatin is an appropriate therapy regardless of health 
      status.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Sama, Shashank
AU  - Sama S
AD  - Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt 
      Lake City, UT 84112, USA.
FAU - Kerrigan, Kathleen
AU  - Kerrigan K
AD  - Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt 
      Lake City, UT 84112, USA.
FAU - Sinnott, Jennifer A
AU  - Sinnott JA
AD  - Statistics Department, Ohio State University, Columbus, OH, USA.
FAU - Puri, Sonam
AU  - Puri S
AD  - Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt 
      Lake City, UT 84112, USA.
FAU - Akerley, Wallace
AU  - Akerley W
AD  - Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt 
      Lake City, UT 84112, USA.
FAU - Haaland, Benjamin
AU  - Haaland B
AD  - Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt 
      Lake City, UT 84112, USA.
FAU - Patel, Shiven
AU  - Patel S
AD  - Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt 
      Lake City, UT 84112, USA. Electronic address: shiven.patel@hci.utah.edu.
LA  - eng
GR  - P30 CA042014/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230121
PL  - England
TA  - Cancer Treat Res Commun
JT  - Cancer treatment and research communications
JID - 101694651
RN  - BG3F62OND5 (Carboplatin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 49DFR088MY (Platinum)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carboplatin/therapeutic use
MH  - Cisplatin/therapeutic use
MH  - *Lung Neoplasms
MH  - Platinum/therapeutic use
MH  - *Small Cell Lung Carcinoma/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chemoradiation
OT  - Platinum therapy
OT  - Radiosensitizer
OT  - Real-world outcomes
OT  - Retrospective analysis
COIS- Declaration of Competing Interest Dr. Haaland served as a consultant for 
      Guidepoint Global, Value Analytics Labs, National Kidney Foundation, and Proxima 
      Clinical Research. Dr. Puri reports receiving consulting/advisory fees from 
      AstraZeneca, G1 therapeutics and Jazz Pharma and also reports travel funding from 
      Dava Oncology. Dr. Patel reports receiving institutional funding from Takeda, 
      Merck, AstraZeneca, Janssen; and consulting fees/advisory board fees from 
      AstraZeneca, Natera, Boehringer Ingelheim, Blueprint Medicines, TerSera 
      Therapeutics, Takeda, Regeneron, and Sanofi. Dr. Akerley reports participation on 
      data safety/ advisory board for Lilly. Jennifer Sinnott reports an NIH funding 
      grant. The remaining authors declare no conflict of interest.
EDAT- 2023/02/04 06:00
MHDA- 2023/05/15 06:42
CRDT- 2023/02/03 18:06
PHST- 2022/11/11 00:00 [received]
PHST- 2023/01/14 00:00 [revised]
PHST- 2023/01/18 00:00 [accepted]
PHST- 2023/05/15 06:42 [medline]
PHST- 2023/02/04 06:00 [pubmed]
PHST- 2023/02/03 18:06 [entrez]
AID - S2468-2942(23)00007-2 [pii]
AID - 10.1016/j.ctarc.2023.100686 [doi]
PST - ppublish
SO  - Cancer Treat Res Commun. 2023;35:100686. doi: 10.1016/j.ctarc.2023.100686. Epub 
      2023 Jan 21.